These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26299635)

  • 1. Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways.
    Zhang J; Yu J; Xie R; Chen W; Lv Y
    Nat Prod Res; 2016 Aug; 30(16):1858-61. PubMed ID: 26299635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/Akt signaling pathway.
    Xu X; Qin J; Liu W
    Gene; 2014 Aug; 546(2):226-32. PubMed ID: 24910117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
    Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
    Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
    Yu P; Ye L; Wang H; Du G; Zhang J; Zhang J; Tian J
    Tumour Biol; 2015 Mar; 36(3):2143-53. PubMed ID: 25398692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
    Koh YW; Shah MH; Agarwal K; McCarty SK; Koo BS; Brendel VJ; Wang C; Porter K; Jarjoura D; Saji M; Ringel MD
    Endocr Relat Cancer; 2012 Feb; 19(1):29-38. PubMed ID: 22109971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
    Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
    Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.
    Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X
    Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RETRACTED ARTICLE: Investigating EGFR-VEGF-mediated apoptotic effect of cucurbitacin D and I combination with sorafenib via Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways.
    Üremis N; Türköz Y; Üremiş MM; Çiğremiş Y; Şalva E
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3247. PubMed ID: 37917368
    [No Abstract]   [Full Text] [Related]  

  • 13. Curcumin induced apoptosis via PI3K/Akt-signalling pathways in SKOV3 cells.
    Yu Z; Wan Y; Liu Y; Yang J; Li L; Zhang W
    Pharm Biol; 2016 Oct; 54(10):2026-32. PubMed ID: 26911246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer.
    Yi H; Ye T; Ge M; Yang M; Zhang L; Jin S; Ye X; Long B; Li L
    Oncol Rep; 2018 Feb; 39(2):711-720. PubMed ID: 29207150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
    Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
    Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
    Carlo-Stella C; Locatelli SL; Giacomini A; Cleris L; Saba E; Righi M; Guidetti A; Gianni AM
    PLoS One; 2013; 8(4):e61603. PubMed ID: 23620775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
    Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
    Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.